E-LIB Suche - Ergebnisse für: Larrey, D.

1

Lomitapide hepatic safety: A long-term retrospective analys..:

Cegla, J. ; Larrey, D. ; D'Erasmo, L...
Atherosclerosis Plus. 54 (2023) - p. S2-S3 , 2023

Link: https://doi.org/10.1016/..

2

Lower compliance to prior HCC surveillance and liver functi..:

Nahon, P. ; Richard, L. ; Valerie, B....
Journal of Hepatology. 68 (2018) - p. S14 , 2018

Link: https://doi.org/10.1016/..

3

Sofosbuvir plus ribavirin and sofosbuvir plus daclatasvir-b..:

Hezode, C. ; De Ledinghen, V. ; Haour, G....
Journal of Hepatology. 68 (2018) - p. S264 , 2018

Link: https://doi.org/10.1016/..

4

Efficacy and safety of 8 weeks of elbasvir/grazoprevir in H..:

Asselah, T. ; Pol, S. ; Hezode, C....
Journal of Hepatology. 68 (2018) - p. S3-S4 , 2018

Link: https://doi.org/10.1016/..

5

Drug exposure and risk of Acute Liver Failure leading to re..:

Larrey, D. ; Meunier, L. ; Pageaux, G.-P....
Journal of Hepatology. 68 (2018) - p. S587-S588 , 2018

Link: https://doi.org/10.1016/..

6

Estimated risk reduction of mortality and transplantation w..:

Corpechot, C. ; Rousseau, A. ; Chazouillères, O....
Journal of Hepatology. 68 (2018) - p. S3-S4 , 2018

Link: https://doi.org/10.1016/..

7

Long-term liver safety of lomitapide in patients with homoz..:

Larrey, D. ; Underberg, J. ; Cannon, C....
Journal of Hepatology. 68 (2018) - p. S588 , 2018

Link: https://doi.org/10.1016/..

8

High efficacy and safety of grazoprevir and elbasvir for 8 ..:

Abergel, A. ; Hezode, C. ; Asselah, T....
Journal of Hepatology. 68 (2018) - p. S110 , 2018

Link: https://doi.org/10.1016/..

9

HCV eradication reduces the occurrence of major adverse car..:

Cacoub, P. ; Nahon, P. ; Layese, R....
Journal of Hepatology. 66 (2017) 1 - p. S20-S21 , 2017

Link: https://doi.org/10.1016/..

10

The negative impact of HBV/HCV coinfection on cirrhosis and..:

Pol, S. ; Haour, G. ; Fontaine, H....
Alimentary Pharmacology & Therapeutics. 46 (2017) 11-12 - p. 1054-1060 , 2017

Link: https://doi.org/10.1111/..

11

A 2-year multicenter, double-blind, randomized, placebo-con..:

Corpechot, C. ; Chazouillères, O. ; Rousseau, A....
Journal of Hepatology. 66 (2017) 1 - p. S89 , 2017

Link: https://doi.org/10.1016/..

12

Effectiveness and cost-effectiveness of antiviral treatment..:

Willmington, C. ; Ganne-Carrié, N. ; Roudot-Thoraval, F....
Journal of Hepatology. 66 (2017) 1 - p. S414-S415 , 2017

Link: https://doi.org/10.1016/..

13

Identifying residual risk of hepatocellular carcinoma follo..:

Audureau, E. ; Bourcier, V. ; Layese, R....
Journal of Hepatology. 66 (2017) 1 - p. S21-S22 , 2017

Link: https://doi.org/10.1016/..

14

The Benefits of Virosuppression on Progression of Portal Hy..:

Bureau, C. ; Thabut, D. ; Layese, R....
Journal of Hepatology. 64 (2016) 2 - p. S655-S656 , 2016

Link: https://doi.org/10.1016/..

15

Prospective Evidence That Hepatocellular Carcinoma Surveill..:

Costentin, C. ; Layese, R. ; Bourcier, V....
Journal of Hepatology. 64 (2016) 2 - p. S194-S195 , 2016

Link: https://doi.org/10.1016/..